Company Monitoring Page for Idorsia

job ratings for Idorsia

06/09/23
industry:
Bio pharmaceutical Industry
company:
Idorsia
job rating:
1
Most toxic environment I have ever worked in.

latest headlines for company on cafepharma

Idorsia's sale of Tryvio falls behind schedule, but layoffs remain on track
Fierce Biotech
Fri, 12/20/24 - 11:22 am
Tags:
Idorsia, hypertension, Tryvio, layoffs
Neurocrine, Idorsia part ways 2 years after collab's double phase 2 fails
Fierce Biotech
Tue, 10/29/24 - 11:32 am
Tags:
Idorsia, Neurocrine, clinical trials, NBI-827104, calcium channel blockers
Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension
Fierce Pharma
Wed, 03/20/24 - 09:49 pm
Tags:
JNJ, Idorsia, Tryvio, hypertension, FDA
Viatris splashes out $350m on pair of Idorsia therapies
Pharmaphorum
Wed, 02/28/24 - 10:45 am
Tags:
Viatris, Idorsia, lupus, myocardial infarction, selatogrel, cenerimod
J&J sends blood pressure drug back to Idorsia
BioPharma Dive
Wed, 09/6/23 - 11:54 am
Tags:
Idorsia, JNJ, aprocitentan, hypertension
Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales
Fierce Biotech
Fri, 07/21/23 - 10:00 am
Tags:
Idorsia, layoffs, Quviviq
Idorsia in Exclusive Talks for up to CHF 400 Million Strategic Deal for Asia Pacific (ex-China) Operations
Globe Newswire
Tue, 06/6/23 - 09:58 am
Tags:
Idorsia, Asia Pacific
Defense Department backs new study of Idorsia's Quviviq as a treatment for PTSD
Fierce Pharma
Wed, 05/10/23 - 09:58 am
Tags:
Idorsia, PTSD, Department of Defense, Quviviq
Idorsia shares sink on ‘unexpected’ failure of drug study
BioPharma Dive
Mon, 02/6/23 - 06:07 pm
Tags:
Idorsia, clinical trials, clazosenta
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
Tags:
clinical trials, Acadia Pharmaceuticals, Argenx, Arrowhead Pharmaceuticals, Biomarin, BioNTech, Daiichi Sankyo, Day One, EQRx, Fate Therapeutics, FibroGen, Gilead Sciences, Idorsia, Immunogen, Intellia Therapeutics, Karuna Therapeutics, Moderna Therapeutics, Regeneron, Roche, Travere Therapeutics, Vaxcyte
Neurocrine's $50M bet on Idorsia drug flames out in second PhII
Endpoints
Wed, 12/7/22 - 09:58 am
Tags:
Neurocrine, Idorsia, clinical trials, NBI-827104, epileptic encephalopathy
J&J, Idorsia plan filings for aprocitentan data in resistant hypertension
Pharmaphorum
Tue, 11/8/22 - 10:33 pm
Tags:
JNJ, Idorsia, aprocitentan, hypertension, resistant hypertension
J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential
Fierce Biotech
Mon, 05/23/22 - 10:19 am
Tags:
JNJ, hypertension, Idorsia, clinical trials, aprocitentan
Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication
Fierce Biotech
Tue, 05/10/22 - 10:39 am
Tags:
Idorsia, clinical trials, ACT-539313, binge eating disorder, Actelion
Idorsia's recently approved insomnia drug Quviviq hits the shelves
Bizjournals
Wed, 05/4/22 - 05:43 pm
Tags:
Idorsia, drug launches, insomnia, Quviviq
Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigo
Fierce Pharma
Mon, 01/10/22 - 11:37 pm
Tags:
Idorsia, Quviviq, insomnia, FDA, Merck, Belsomra
Idorsia hoping to make its dreams come true with a new insomnia alliance
Fierce Pharma
Tue, 12/14/21 - 11:06 am
Tags:
Idorsia, insomnia, pharma marketing, daridorexant
Idorsia sets itself up for failure
EP Vantage
Mon, 11/1/21 - 10:57 pm
Tags:
Idorsia, cenerimod, lupus, clinical trials
Late-stage letdown for lucerastat dents Idorsia stock
Pharma Letter
Mon, 10/11/21 - 10:20 am
Tags:
Idorsia, clinical trials, lucerastat, Fabry disease
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Wed, 09/2/20 - 11:04 am
Tags:
Santhera, vamorolone, Duchenne Muscular Dystrophy, Idorsia, ReveraGen

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.